The study demonstrated that valdecoxib inhibits the ATF4-CHOP pathway in “I/R-induced glaucoma-like” damaged cells, providing potential insights into its therapeutic efficacy in glaucoma management [253]. This evidence concerns the gene DDIT3 and glaucoma.